This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

William E. Hathaway, MD

JAMA. 1985;253(8):1167.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Danazol is a 2,3-isoxazol derivative of 17 -ethinyl testosterone; it is known to be an anabolic steroid with mild androgenic activity. The administration of the drug is associated with raised plasma levels of several proteins including prealbumin, haptoglobulin, transferrin, antithrombin III, prothrombin, plasminogen, ₁-antitrypsin, and Cl esterase inhibitor.^1,2 Last year Gralnick and Rick¹ reported evidence that danazol was associated with increased levels of factor VIIIc and factor IX and decreased transfusion requirements in patients with hemophilia. Subsequent studies by Gralnick and associates⁴ as well as other studies by Garewal et al⁵ are reported in this issue of THE JOURNAL and form the basis for this commentary.

The readers of the aforementioned articles are faced with a dilemma in judging the usefulness of danazol in management of hemophilia patients. Gralnick et al report on three of their initial patients plus eight French patients with hemophilia A. . . . [Full Text PDF of this Article]

Author Affiliations
University of Colorado Health Sciences Center Denver

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?